MedImmune, the R&D department of pharma giant AstraZeneca, has licensed the rights to develop and test cancer-fighting drugs to Yale spin-out Koltan Pharmaceuticals.

Spun out of the University’s School of Medicine in 2007, the US-based life sciences firm Koltan intends to develop the drug, which has been designed to target a receptor connected to cancers include breast, ovary, colon and lung.

Both companies will have the potential for future cost, risk and profit sharing for the product, which should commence…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?